Cynanchum bungei fermented and purified C21 steroidal glycoside for resisting hepatic fibrosis
By fermenting and purifying the C21 steroidal glycoside in Polygonum multiflorum, a drug was prepared for the treatment of liver fibrosis, which solved the shortcomings of existing Western medicines in the treatment of liver fibrosis, and achieved the effect of significantly inhibiting the proliferation of precursor collagen cells and reducing liver hardness and hydroxyproline content.
Patent Information
- Application Number
- CN202510254787.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-03-05
- Publication Date
- 2025-06-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
At present, no exact and effective Western medicine has been found to treat liver fibrosis. Its complex pathogenesis makes existing treatment methods limited. Traditional Chinese medicine has potential in this field but has not yet been fully utilized.
By fermenting the C21 steroidal glycoside in Polygonum multiflorum, a drug that significantly inhibits the proliferation of precursor collagen cells and reduces liver hardness and hydroxyproline content was prepared for the treatment of liver fibrosis.
The fermentation purified C21 sterosinolate of Polygonum multiflorum can significantly inhibit the proliferation of precursor collagen cells, reduce liver hardness and hydroxyproline content, and is better than the commonly used ergosaponin, and has shown good results in the treatment of liver fibrosis.
Smart Images

Figure CN120078837A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of pharmaceutical development, and particularly relates to a cynanchum bungei steud fermentation pure compound C 21 steroidal glycoside for use in anti-hepatic fibrosis. Background Art
[0002] Hepatic fibrosis is a common pathological process of chronic liver diseases caused by various etiologies such as viral hepatitis and alcoholism, and can progress to liver cirrhosis and even liver cancer, seriously threatening human health. At present, its pathogenesis has not been fully clarified. The key link is the activation of hepatic stellate cells and their further transformation into myofibroblasts. The characteristic manifestations are excessive proliferation and abnormal deposition of a large amount of extracellular matrix, resulting in liver structure damage and the formation of pseudolobules. At the same time, hepatic fibrosis is accompanied by disorders of various cytokines and oxidative stress responses, etc. This process involves multiple important signal transduction pathways in the body. In the treatment of hepatic fibrosis, due to its complex pathogenesis, no exact and effective western medicine has been found yet. Traditional Chinese medicine has the characteristics of "multiple components - multiple targets - multiple pathways" in inhibiting the progression of hepatic fibrosis and promoting the reversal of hepatic fibrosis, and has made relatively good progress in the research and treatment of liver diseases including hepatic fibrosis. Some single Chinese herbs, Chinese medicine compounds, and Chinese medicine monomers (such as lactones, flavonoids, glycosides, alkaloids, etc.) can effectively inhibit the development of hepatic fibrosis through mechanisms such as antioxidant, anti-inflammatory, regulation of apoptosis, and inhibition of HSC activation. A large number of studies have shown that cynanchum bungei steud 21 steroidal glycoside has good preventive and therapeutic effects on hepatic fibrosis. Zhuang Zirui et al. established a combined model of hepatic and renal fibrosis by using thioacetamide combined with unilateral ureteral ligation to explore the regulatory mechanism of cynanchum bungei steud 21 steroidal glycoside in the simultaneous prevention and treatment of hepatic and renal fibrosis, indicating that cynanchum bungei steud 21 steroidal glycoside can significantly inhibit the damage to liver and kidney functions caused by thioacetamide combined with unilateral ureteral ligation, reduce collagen deposition in hepatic and renal tissues, and the pathological results also show that cynanchum bungei steud 21 steroidal glycoside can reduce the degree of hepatic and renal tissue lesions and reduce inflammatory cell infiltration. At present, there is no literature report on the new use of cynanchum bungei steud fermentation pure compound C 21 steroidal glycoside in anti-hepatic fibrosis. Summary of the Invention
[0003] The purpose of the present invention is to provide an application of cynanchum bungei steud fermentation pure compound C 21 steroidal glycoside. Cynanchum bungei steud fermentation pure compound C 21 steroidal glycoside has the effects of significantly inhibiting the proliferation of precollagen cells, as well as reducing the LSM value and hydroxyproline content, and can be used for the preparation of anti-hepatic fibrosis drugs or drugs for the treatment of hepatic fibrosis.
[0004] The present invention is implemented as follows: A cynanchum bungei steud fermentation pure compound C21 Use of steroidal glycosides in the preparation of drugs for treating liver fibrosis or fibrosis
[0005] Preferably, the Cynanchum bungei Steud. fermented pure compound C 21 Steroidal glycosides are used for preparing drugs for inhibiting the proliferation of pre - collagen cells of hepatic stellate cells, and for preparing drugs for reducing the LSM value and hydroxyproline content of hepatocytes.
[0006] Preferably, the dosage forms of the drugs include injections, decoctions, and pills.
[0007] In the present invention, the above - mentioned Cynanchum bungei Steud. fermented pure compound C 21 The preparation method of steroidal glycosides comprises the following steps:
[0008] (1) Take 250 g of fresh roots of Cynanchum bungei Steud., add 35 mL of distilled water and 100 g of cross - linked enzyme preparation (amylase: glucoamylase = 1:1) to prepare a Cynanchum bungei Steud. root saccharification solution. Dilute it with Czapek - dox medium and inoculate with endophytic bacteria of Cynanchum bungei Steud. (inoculation amount is 3%), and culture it for 120 h under the conditions of 32 °C, pH 8, and shaking at 120 rpm to obtain a fermentation broth;
[0009] (2) After centrifuging the above - mentioned fermentation broth at 10,000 rmp for 10 min, remove the supernatant and perform freeze - drying. Add the obtained freeze - dried powder to anhydrous ethanol, homogenize it and then let it stand. Collect the supernatant, add a precipitating agent (ether: acetone = 1:1 - 2), and let it stand for 2 h;
[0010] (3) Filter the obtained precipitation solution by suction filtration, collect the precipitate, and evaporate it until no liquid residue remains, thus obtaining the Cynanchum bungei Steud. fermented pure compound C 21 Steroidal glycosides.
[0011] The present invention further discloses a method for determining the drug concentration of Cynanchum bungei Steud. fermented pure compound C 21 Steroidal glycosides: Set gradient concentrations for the samples (20, 40, 60, 80 μg / mL), treat MHSteC mouse hepatic stellate cells with the samples for 24 h, and detect the hydroxyproline content with an amino acid auto - analyzer. It is determined that the anti - liver fibrosis ability of Cynanchum bungei Steud. fermented pure compound C 21 Steroidal glycosides is better after treatment. According to the conversion of body surface area, the equivalent dose range for rats is 10 - 12 mg / kg.
[0012] The present invention further discloses a method for detecting the inhibition rate of Cynanchum bungei Steud. fermented pure compound C 21 Steroidal glycosides on the proliferation of pre - collagen cells: Treat MHSteC mouse hepatic stellate cells with the sample for 24 h (40 μg / mL). Detect the cell survival rate with an enzyme - linked immunosorbent assay (ELISA) reader, calculate its average inhibition rate according to the formula, and the average inhibition rate result is 53.72%.
[0013] The present invention further discloses Cynanchum bungei Decne. fermentation pure compound C 21 Detection method for the effect of steroidal glycosides on liver stiffness: The liver fibrosis model rats were treated by intragastric administration of the sample once a day (10 mg / kg) for 28 consecutive days. Take the liver tissue samples of the rats, and measure the liver stiffness value with a liver cirrhosis detector. The detection result is 7.4 kPa.
[0014] The present invention further discloses Cynanchum bungei Decne. fermentation pure compound C 21 Detection method for the effect of steroidal glycosides on the content of hydroxyproline in the liver: The sample treatment method is the same as above. Take the liver tissue samples of the rats, fully hydrolyze them, and detect the content of hydroxyproline with an amino acid analyzer, which is 0.278 mg·g -1 。
[0015] Compared with the disadvantages and deficiencies of the prior art, the present invention has the following beneficial effects: The present invention provides the application of Cynanchum bungei Decne. fermentation pure compound C 21 steroidal glycosides in the preparation of drugs for the treatment of liver fibrosis. Through cell and animal experiments, the present invention finds that the Cynanchum bungei Decne. fermentation pure compound C 21 steroidal glycosides can inhibit the proliferation of precursor collagen cells; and can significantly reduce the liver stiffness value (LSM value) and the content of hydroxyproline in the liver tissue of the model rats. The key anti-liver fibrosis related index data are better than those of the commonly used ergosterol saponin at present, and it has broad application prospects. Description of the Drawings
[0016] Figure 1 is the LC-MS detection result of Cynanchum bungei Decne. fermentation pure compound C 21 steroidal glycosides (purified product of Agrobacterium tumefaciens F-45 fermentation broth);
[0017] Figure 2 is the measured value of liver stiffness in rats after drug administration in the present invention;
[0018] Figure 3 is the content of hydroxyproline in the liver of rats after drug administration in the present invention. Detailed Embodiments
[0019] In order to make the objectives, technical solutions and advantages of the present invention clearer, the present invention will be further described in detail below with reference to the drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention, and are not used to limit the present invention.
[0020] Example 1 Preparation of Cynanchum bungei Decne. fermentation pure compound C 21 steroidal glycosides
[0021] Take 250 g of fresh roots of Cynanchum bungei, add 35 mL of distilled water and 100 g of cross-linked enzyme preparation (amylase: glucoamylase = 1:1) to prepare a Cynanchum bungei root saccharification solution, dilute it with Gao's No. 1 medium and inoculate Agrobacterium tumefaciens F-45 (i.e., the endophyte of Cynanchum bungei, the inoculation amount is 3%), and culture it under the conditions of 32 °C, pH 8 and shaking at 120 rpm for 120 h to obtain a fermentation broth. After centrifuging the above fermentation broth at 10,000 rmp for 10 min, take the supernatant for freeze-drying. The obtained freeze-dried powder is homogenized in absolute ethanol and then allowed to stand. Collect the supernatant, add a precipitating agent (ether: acetone = 1:1 - 2), allow it to stand for 2 h, then filter the obtained precipitated solution, collect the precipitate, and evaporate until there is no liquid residue, thus obtaining the pure Cynanchum bungei fermentation product C 21 Steroidal glycoside.
[0022] For the pure Cynanchum bungei C 21 steroidal glycoside fermentation product prepared in the above example, perform HPLC detection and LC-MS identification. Chromatographic parameters: Alltima C18 chromatographic column (250 mm × 4.6 mm, 5 μm); gradient elution with acetonitrile (A)-water (B) (0 - 10 min, 35% A.); flow rate 1 mL / min; column temperature 35 °C; detection wavelength 263 nm; injection volume 10 μL. Mass spectrometry parameters are: ESI positive ion mode, MSE Continum acquisition mode; spray voltage 5 kV; desolvation gas is nitrogen, flow rate 1000 L / h, desolvation temperature 550 °C, ion source temperature 100 °C, scanning range m / z 50 - 1500, collision gas is argon.
[0023] The above Cynanchum bungei C 21 steroidal glycoside fermentation product was analyzed by LC-MS as C 21 steroidal compound, which is kedogenin ( Figure 1 ).
[0024] In the example of the present invention, the above Agrobacterium tumefaciens F-45 was deposited at the China Center for Type Culture Collection on September 13, 2021, with the deposit number CCTCC NO: M20211166, and the deposit address is: Wuhan University, Wuhan, China, and the postal code is 430072.
[0025] Example 2 Experiment on the anti-hepatic fibrosis effect of the fermentation product at the cellular level
[0026] The pure Cynanchum bungei fermentation product C 21 Effect of steroidal glycoside drug treatment on the proliferation inhibition rate of mouse MHSteC precollagen cells
[0027] Materials: MHSteC mouse hepatic stellate cells (Mingzhoubio MZ-7964)
[0028] Instrument: Microplate Reader (Molecular Devices)
[0029] After the resuscitation of MHSteC mouse hepatic stellate cells, they were transferred to a 48-well culture plate and cultured for 6 h. Control group (not treated with the sample), experimental group (treated with the sample), and blank group (only containing culture medium and detection reagents) were set up. The sample (40 μg / mL) was added, and under the same culture conditions, they were cultured for 24 h. CCK-8 was added to the cells of each group and allowed to act for 3 h. The microplate reader measured the absorbance values of each group at a wavelength of 540 nm. Record the OD value of the control group (A C ), the OD value of the experimental group (A S ), and the OD value of the blank group (A B ), and calculate its average inhibition rate according to the formula. The proliferation rate of precollagen cells of the sample on mouse hepatic stellate cells was calculated according to the following formula:
[0030] Cell proliferation inhibition rate (%) = [(A C - A S ) / (A C - A B )] × 100%
[0031] In the formula: A c : Absorbance of the control group, containing cells and sample treatment;
[0032] A S : Absorbance of the experimental group, containing cells and sample;
[0033] A B : Absorbance of the blank group, without cells and sample.
[0034] The results are shown in Table 1 below.
[0035] Table 1 Proliferation inhibition rate of precollagen cells
[0036]
[0037] As can be seen from Table 1, the inhibitory rate of the proliferation of precollagen cells of Cynanchum bungei fermented pure compound C 21 steroidal glycosides on mouse MHSteC precollagen cells is higher than that of the control group. The inhibitory rate of the proliferation of precollagen cells of Cynanchum bungei fermented pure compound C 21 steroidal glycosides is the highest at a treatment concentration of 40 μg / mL, which is 53.72%.
[0038] Example 3 Experimental design and process of the anti-hepatic fibrosis effect of fermented pure compound at the animal level
[0039] (1) Effect of Cynanchum bungei fermented pure compound C 21 steroidal glycosides treatment on the hardness of rat liver tissue
[0040] Instrument: Shanghai Baosheng Technology Biological Tissue Mechanics Tester
[0041] In this experiment, Servicebio CCL 4 induced liver fibrosis model rats, 6 weeks old, with a body weight of approximately 200 - 230 g, were raised in an animal house with a constant temperature of (25 ± 3°C), a constant humidity of (50 ± 10%), and a cyclic light-dark cycle of 12 / 12 h light / dark, and ventilation was maintained. The model group, the experimental group (receiving sample treatment), and the positive group (receiving ergosterol saponin treatment) were set up. The liver fibrosis model rats were treated by gavage with the sample once a day (10 mg / kg) for 28 consecutive days. The liver tissues of the rats were taken, rinsed clean with physiological saline, and after removing the surface blood, fat, and other contaminants, the tissues were cut into appropriate-sized samples, and the liver hardness value was measured using a liver cirrhosis detector.
[0042] The test results are as Figure 2 shown. It can be seen from Figure 2 that the treatment of rat liver tissue with cynanchum bungei fermented pure compound C 21 steroidal glycosides was lower than that of the model group and the positive group. Cynanchum bungei fermented pure compound C 21 steroidal glycosides had the lowest liver hardness value at a treatment concentration of 10 mg / kg (rat body weight), which was 7.4 ± 0.212 Kpa, significantly lower than that of the model group (P < 0.01).
[0043] (2) Effect of cynanchum bungei fermented pure compound C 21 steroidal glycosides on the hydroxyproline content in the rat liver Instrument: Automatic Amino Acid Analyzer (Hitachi L-8900 series)
[0044] The sample method was the same as above. The liver tissue samples of the rats were taken out and placed in pre-cooled enzyme-free EP tubes, and immediately stored frozen in a -80°C refrigerator. An appropriate amount of sample was taken from the frozen liver tissue for acid hydrolysis, and the hydrolysis conditions were: 110°C, 6 mol / L, hydrolysis for 12 h. After sufficient hydrolysis, the hydroxyproline content was detected using an automatic amino acid analyzer.
[0045] The analysis results are as Figure 3 shown. It can be seen from Figure 3 that the treatment of rat liver hydroxyproline content with cynanchum bungei fermented pure compound C 21 steroidal glycosides was lower than that of the model group and the positive group. Cynanchum bungei fermented pure compound C 21 steroidal glycosides had the lowest hydroxyproline content at a treatment concentration of 10 mg / kg (rat body weight), which was 0.278 ± 0.0322 mg / g, significantly lower than that of the model group (P < 0.05).
[0046] In summary, compared with the model group, cynanchum bungei fermented pure compound C 21Steroidal glycosides have a good effect on anti - liver fibrosis.
[0047] The above are only the preferred embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent substitutions, and improvements made within the spirit and principle of the present invention shall be included within the protection scope of the present invention.
Claims
1. A kind of Radix Cynanchum multiflorum fermentation purified product C 21 Application of steroidal glycosides in the preparation of anti-liver fibrosis drugs or fibrosis treatment drugs.
2. The use according to claim 1, characterized in that The fermented purified product C 21 Steroidal glycosides are used to prepare drugs for inhibiting the proliferation of hepatic stellate cell precursor collagen cells, and for preparing drugs for reducing the LSM value and hydroxyproline content of hepatocytes.
3. The use according to claim 1, characterized in that The dosage forms of the drug include injection, decoction and pills.
